case_images: PMC11787603_01
case_images: X-ray from chest patient and respective plasma analysis of valproic acid and quetiapine by GC-MS and LC-UV/Vis. (I) X-ray from chest patient demonstrating gross perihilar infiltrate (red line) in right lung of the patient. (II-A) Blank plasma for valproic acid analysis by GC-MS; (II-B) Blank plasma sample spiked with 50 mug/mL of valproic acid; (II-C) Real sample diluted 20 times containing 977.96 microg/mL of valproic acid; (III-D) Blank plasma sample spiked with 200 ng/mL of IS for quetiapine analysis by LC-UV/Vis; (III-E) Blank plasma sample spiked with 150 and 500 ng/mL of quetiapine; (III-F) Real sample detected quetiapine in plasma sample from patient (> 150 ng/mL). GC-MS, gas chromatography coupled mass spectrometry; LC-UV/Vis, liquid chromatography with ultraviolet/visible; L, left; R, right.
case_images: gr1.jpg
case_images: PMC11787603_01_gr1.jpg
case_images: fig0005
case_images: Chest X-ray was performed and presented a gross perihilar infiltrated (Fig. 1-I). Gas chromatography coupled to mass spectrometry (GC-MS) after liquid-liquid extraction was employed and demonstrated 977.96 microg/mL of VPA (therapeutic range: 50-100 microg/mL) while liquid chromatography with ultraviolet-visible detector (LC-UV/Vis) identified QP above limit of detection (150 ng/mL) (Fig. 1- II and III).